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Abstract
Physiologic anti-inflammatory mechanisms are selected by
evolution to control the immune system and to prevent infectious
and inflammatory disorders. Central-acting α2-agonists attenuate
systemic inflammation and improve survival in experimental sepsis.
This anti-inflammatory and therapeutic mechanism of central sym-
patholytics appears to be mediated by an unexpected vagomimetic
potential of the α2-agonists to activate the vagus nerve. Recent
studies, however, rule out a cholinergic anti-inflammatory
mechanism based on a direct cholinergic interaction between the
vagus nerve and the immune system. Since the nervous system is
the principal regulator of the immune system, physiologic studies
understanding the neuroimmune connections can provide major
advantages to design novel therapeutic strategies for sepsis.
In the previous issue of Critical Care, Hofer and colleagues
reported that central sympatholytics attenuate systemic
inflammation and improve survival in experimental sepsis [1].
α2-Adrenoceptors close a negative feedback loop in the
neuronal synapses to limit catecholamine production. α2-
Agonists (clonidine and dexmedetomidine) therefore mimic a
physiological condition of high levels of catecholamines and
inhibit the noradrenergic neurotransmission in the medulla
oblongata. The clinical implications of the central-acting α2-
agonists reveal an unexpected sedative potential that is in
part mediated by a proposed vagomimetic potential of these
agonists to activate the vagus nerve [2]. The anti-inflam-
matory and therapeutic potential of central sympatholytics
can therefore be mediated by the vagus nerve. This
mechanism would be similar to that described for
cholecystokinin, semapimod, ghrelin, leptin and melanocortin
peptide, which control immune responses via the vagus
nerve, as surgical vagotomy abrogates their anti-inflammatory
potential [3]. Future studies with surgical vagotomy are
needed to confirm that the vagus nerve mediates the anti-
inflammatory potential of central sympatholytics.
The studies of Hofer and colleagues suggest that central
sympatholytics may control systemic inflammation by inhibit-
ing NF-κB and cytokine production in the liver [1]. If the
vagus nerve mediates the anti-inflammatory potential of the
α2-agonists, however, central sympatholytics may modulate
systemic inflammation through a mechanism mediated by the
spleen [4]. Recent studies indicate that the spleen is a major
source of inflammatory cytokines in experimental sepsis, as
splenectomy attenuates systemic inflammation and protects
against sepsis. The spleen is required for the anti-
inflammatory potential of the vagus nerve. Vagus nerve
stimulation inhibits systemic TNF levels in control animals but
not in splenectomized animals [5]. Likewise, nicotinic agonists
prevent systemic inflammation and improve survival in control
animals but not in splenectomized animals. These studies
might have clinical implications as they may not be beneficial
for patients with a compromised or damaged spleen.
Rosas-Ballina and colleagues have recently demonstrated
that there is no cholinergic connection between the vagus
nerve and immune cells in the spleen [6]. The vagus nerve
does not innervate the spleen, and vagal immunomodulation
in experimental sepsis is mediated by postganglionic
catecholaminergic fibers from the celiac mesenteric plexus
traveling through the splenic nerve [6]. Unlike central-acting
drugs, peripheral sympatholytics can prevent the anti-
inflammatory potential of the vagus nerve and enhance
systemic inflammation in sepsis.
Can NF-κB predict the outcome of sepsis? Since NF-κB is a
key regulator of cytokine production, NF-κB inhibition can
modulate systemic inflammation [4]. A characteristic example
is that the protection of RAGE-deficient mice from sepsis
correlates with NF-κB inactivation in the lung and peritoneum.
NF-κB, however, also protects parenchyma cells from
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cytotoxicity and cell death [7,8]. The most characteristic
example is that p65RelA and IKK knockout mice exhibit
embryonic death resulting from extensive TNFα-mediated
fetal hepatocyte apoptosis. Consistently, disruption of TNFα
signaling – either by removing TNFα or TNF receptor 1 –
prevents this hepatocyte apoptosis in rela–/– mice, allowing
embryonic development to birth. In agreement with these
studies, inhibition of NF-κB after partial hepatectomy results
in massive hepatocyte apoptosis and impairs liver function.
Conversely, NF-κB activation in the liver prevents hepatic
injury during ischemia and reperfusion. NF-κB inhibition
produces different effects in enterocytes, however, and can
prevent intestinal derangements during sepsis. These studies
suggest that the ubiquitous inhibition of NF-κB may not
generate an overall beneficial effect especially in the liver,
unless the therapy targets specific organs or immune cells.
Future studies are needed to determine the molecular and
cellular mechanism by which central sympatholytics modulate
the different NF-κB pathways in sepsis.
What is the therapeutic time frame for experimental sepsis?
Pre-emptive treatment with central sympatholytics started 12
hours before cecal ligation and puncture (CLP) provides
survival benefits, but not if the treatment was started 1 hour
after the surgical procedure [1]. One potential explanation for
this is that the early phase of sepsis is characterized by high
concentrations of circulating catecholamines, which can
boost the initial inflammatory responses. The endogenous
production of catecholamines decreases during the progres-
sion of sepsis, however, and can become insufficient for the
homeostasis of the cardiovascular system (as indicated by
the need for catecholamine administration during septic
shock) [9]. Late inhibition of catecholamines can therefore be
rather detrimental. Another consideration is that ketamine, the
anesthetic used for CLP surgery by Hofer and colleagues, is
a noncompetitive inhibitor of nicotinic receptors that can limit
the anti-inflammatory potential of the vagus nerve. Since the
half-life of ketamine is approximately 3 hours, this anesthetic
may limit the effect of sympatholytics administered 1 hour
after the CLP.
Previous studies from Hofer and colleagues also indicate that
pharmacologic cholinesterase inhibition with physostigmine
or neostigmine improved survival in experimental sepsis when
the treatment was started immediately after the CLP [10]. A
significant trend toward protection was observed when the
treatment was started 6 hours after the surgical procedure.
Yet the authors noted this protection was not statistically
significant (P = 0.057), probably due to the small sample size
[10]. An important consideration is that these strategies can
be limited by a potential cholinergic attrition that limits
acetylcholine production by the vagus nerve during sepsis.
Since vagus nerve stimulation requires α7-nicotinic acetyl-
choline receptors, direct activation of this receptor using
nicotinic agonists may prevent this potential cholinergic
attrition during the progression of sepsis. Indeed, nicotine
improved survival in experimental sepsis even when the
treatment was delayed 24 hours after CLP [11]. Similar
results have been confirmed by other investigators using
selective α7-nicotinic acetylcholine receptor agonists. On the
other hand, there are significant differences in these studies
that can contribute to these late therapeutic benefits. The two
studies use different models of sepsis (with or without
antibiotics) and mice with different gender, age and genetic
background (female C57BL/6 mice 12 to 16 weeks old
versus male BALB/c mice 6 to 8 weeks old). Hofer and
colleagues do not use antibiotics to prevent their inter-
ferences with the immune responses [1], whereas Wang and
colleagues used antibiotics to mimic clinical settings [11]. It
is possible that the use of antibiotics may limit bacteremia
induced by CLP and may favor the benefits of delayed
treatment with nicotinic agonists.
Future studies are needed to determine the therapeutic time
window of central sympatholytics and how this window may
be affected by genetic background, sex, gender and
antibiotics both in clinical and experimental models.
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